Anavex Life Sciences
Anavex Life Sciences (AVXL) presented new data from the Phase IIb/III study showing that blarcamesine (ANAVEX®2-73), once daily orally, demonstrates pre-specified clinical efficacy through upstream SIGMAR1 activation.

Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company developing novel therapeutics to treat neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. The company aims at treating pain, Alzheimer's . . .